- Assessing proarrhythmic potential of drugs when optimal studies are infeasibleEdwin P Rock
GlaxoSmithKline R and D, King of Prussia, PA 19406 0930, USA
Am Heart J 157:827-36, 836.e1. 2009..In these instances, alternative approaches to QT risk assessment must be considered. This article presents points to consider for evaluation of QT risk when alternative approaches are needed...